The concern of generic challenges has long loomed above copyright’s iconic drug, Sildenafil, sparking questions about the prospects of related pharmaceutical portfolios. While early times saw significant returns, the exclusivity lapse has allowed the door for discounted copies, likely reducing profitability and posing a significant hazard for inv